Diabetes, Vol 43, Issue 3 396-402, Copyright © 1994 by American Diabetes Association

ARTICLES

[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin

DC Howey, RR Bowsher, RL Brunelle and JR Woodworth
Lilly Laboratory for Clinical Research, Eli Lilly and Company, Indianapolis, IN 46202.

[Lys(B28, Pro(B29)]-human insulin (LYSPRO) is an insulin analogue in which the natural amino acid sequence of the B-chain at positions 28 and 29 is inverted. These changes result in an insulin molecule with a greatly reduced capacity for self-association in solution. These clinical studies were designed to compare LYSPRO with human Regular insulin after subcutaneous injection in humans. We wanted to evaluate the effect of adding zinc to LYSPRO on its pharmacokinetics and pharmacodynamics. In addition, we compared the pharmacokinetics and pharmacodynamics of LYSPRO and human Regular insulin after subcutaneous injection to those of human Regular insulin given intravenously. Thus, we compared four treatments: solutions of zinc-free LYSPRO given subcutaneously (A), zinc-containing LYSPRO given subcutaneously (B), human Regular insulin given subcutaneously (C), and human Regular insulin given intravenously (D). We gave a 10-U dose of each treatment to 10 healthy (nondiabetic) men during glucose clamps. Serum insulin concentrations peaked more than two times higher (maximum serum insulin level [Cmax], 698 vs. 308 pM, A vs. C) and in less than half the time (time to Cmax [Tmax], 42 vs. 101 min, A vs. C) after subcutaneous injection of zinc-free LYSPRO. At the same time, the glucose infusion rate peaked in about half the time (time to maximum glucose infusion rate [TRmax], 99 vs. 179 min, A vs. C) and was slightly but not significantly higher (maximum glucose infusion rate [Rmax], 3.1 vs. 2.2 mmol/min, A vs. C) than that of human Regular insulin.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. R. Mathiesen, B. Kinsley, S. A. Amiel, S. Heller, D. McCance, S. Duran, S. Bellaire, A. Raben, and on behalf of the Insulin Aspart Pregnancy Study Gr Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women Diabetes Care, April 1, 2007; 30(4): 771 - 776. [Abstract] [Full Text] [PDF]

				the Diabetes Research in Children Network (DirecNe Prevention of Hypoglycemia During Exercise in Children With Type 1 Diabetes by Suspending Basal Insulin Diabetes Care, October 1, 2006; 29(10): 2200 - 2204. [Abstract] [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				A. D. Mooradian, M. Bernbaum, and S. G. Albert Narrative Review: A Rational Approach to Starting Insulin Therapy Ann Intern Med, July 18, 2006; 145(2): 125 - 134. [Abstract] [Full Text] [PDF]

				A. E. Panteleon, M. Loutseiko, G. M. Steil, and K. Rebrin Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes, July 1, 2006; 55(7): 1995 - 2000. [Abstract] [Full Text] [PDF]

				S. N. Davis and S. M. Renda Treating to Target in Type 2 Diabetes: A Case Presentation. The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S. [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				K. Rave, S. Bott, L. Heinemann, S. Sha, R. H.A. Becker, S. A. Willavize, and T. Heise Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin Diabetes Care, May 1, 2005; 28(5): 1077 - 1082. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				R. Retnakaran, J. Hochman, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c Diabetes Care, November 1, 2004; 27(11): 2590 - 2596. [Abstract] [Full Text] [PDF]

				R. Boskovic, D. S. Feig, L. Derewlany, B. Knie, G. Portnoi, and G. Koren Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies Diabetes Care, May 1, 2003; 26(5): 1390 - 1394. [Abstract] [Full Text] [PDF]

				S. Loukovaara, I. Immonen, K. A. Teramo, and R. Kaaja Progression of Retinopathy During Pregnancy in Type 1 Diabetic Women Treated With Insulin Lispro Diabetes Care, April 1, 2003; 26(4): 1193 - 1198. [Abstract] [Full Text] [PDF]

				S. E. Fineberg, J. Huang, R. Brunelle, K. S. Gulliya, and J. H. Anderson Jr Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes Diabetes Care, January 1, 2003; 26(1): 89 - 96. [Abstract] [Full Text] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				P. Luo, R. J. Hayes, C. Chan, D. M. Stark, M. Y. Hwang, J. M. Jacinto, P. Juvvadi, H. S. Chung, A. Kundu, M. L. Ary, et al. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening Protein Sci., May 1, 2002; 11(5): 1218 - 1226. [Abstract] [Full Text] [PDF]

				J. D. Meece and R. K. Campbell Insulin Lispro Update The Diabetes Educator, March 1, 2002; 28(2): 269 - 277. [Abstract] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				A. Moran, J. Phillips, and C. Milla Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis-Related Diabetes Diabetes Care, October 1, 2001; 24(10): 1706 - 1710. [Abstract] [Full Text] [PDF]

				E. Tsui, A. Barnie, S. Ross, R. Parkes, and B. Zinman Intensive Insulin Therapy With Insulin Lispro: A randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection Diabetes Care, October 1, 2001; 24(10): 1722 - 1727. [Abstract] [Full Text] [PDF]

				K. Rave, T. Heise, A. Pfützner, L. Heinemann, and P. T. Sawicki Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients Diabetes Care, May 1, 2001; 24(5): 886 - 890. [Abstract] [Full Text]

				H. Chen, M. Shi, Z.-Y. Guo, Y.-H. Tang, Z.-S. Qiao, Z.-H. Liang, and Y.-M. Feng Four new monomeric insulins obtained by alanine scanning the dimer-forming surface of the insulin molecule Protein Eng. Des. Sel., November 1, 2000; 13(11): 779 - 782. [Abstract] [Full Text] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				B. Guerci, L. Meyer, A. Sallé, A. Charrié, B. Dousset, O. Ziegler, and P. Drouin Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2673 - 2678. [Abstract] [Full Text]

				R. J. Mahler and M. L. Adler Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1165 - 1171. [Full Text]

				J. Ung, M. Hu, T. Hagerup, and R. K. Campbell Lispro Insulin: Adsorption and Stability in Selected Intravenous Devices The Diabetes Educator, March 1, 1999; 25(2): 237 - 245. [Abstract] [PDF]

				R. R. Bowsher, R. A. Lynch, P. Brown-Augsburger, P. F. Santa, W. E. Legan, J. R. Woodworth, and R. E. Chance Sensitive RIA for the Specific Determination of Insulin Lispro Clin. Chem., January 1, 1999; 45(1): 104 - 110. [Abstract] [Full Text] [PDF]

				S. Lin, L.-L. H. Chen, and Y. W. Chien Comparative Pharmacokinetic and Pharmacodynamic Studies of Human Insulin and Analogues in Chronic Diabetic Yucatan Minipigs J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 959 - 966. [Abstract] [Full Text]

				M. T. Travaglini, S. K. Garg, and H. P. Chase Use of Insulin Lispro in the Outpatient Management of Ketonuria Arch Pediatr Adolesc Med, July 1, 1998; 152(7): 672 - 675. [Abstract] [Full Text] [PDF]

				K. S. Rutledge, H. P. Chase, G. J. Klingensmith, P. A. Walravens, R. H. Slover, and S. K. Garg Effectiveness of Postprandial Humalog in Toddlers With Diabetes Pediatrics, December 1, 1997; 100(6): 968 - 972. [Abstract] [Full Text] [PDF]

				F. Holleman and J. B.L. Hoekstra Insulin Lispro N. Engl. J. Med., July 17, 1997; 337(3): 176 - 183. [Full Text] [PDF]

				M. R. Burge, D. L. Waters, J. H. Holcombe, and D. S. Schade Prolonged Efficacy of Short Acting Insulin Lispro in Combination with Human Ultralente in Insulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 920 - 924. [Abstract] [Full Text] [PDF]

				J. L. Betz Fast-Acting Human Insulin Analogs: A Promising Innovation in Diabetes Care The Diabetes Educator, January 1, 1995; 21(3): 195 - 200. [PDF]

				J. Fawcett, F. G. Hamel, R. G. Bennett, Z. Vajo, and W. C. Duckworth Insulin and Analogue Effects on Protein Degradation in Different Cell Types. DISSOCIATION BETWEEN BINDING AND ACTIVITY J. Biol. Chem., April 6, 2001; 276(15): 11552 - 11558. [Abstract] [Full Text] [PDF]